Advertisement

Epidemiology of Diffuse Low-Grade Gliomas

  • Luc BauchetEmail author
Chapter

Abstract

Diffuse low-grade gliomas (DLGGs) belong to primary central nervous system tumors (PCNSTs) and include diffuse astrocytomas (fibrillary astrocytoma, gemistocytic astrocytoma, protoplasmic astrocytoma), oligodendroglioma, and oligoastrocytoma.

Specific epidemiological publications of DLGG are very rare. However, it is possible to obtain epidemiological data concerning DLGG by selecting some publications referring to all PCNSTs, gliomas, or even to low-grade gliomas (LGGs). (We will show that the term “LGG” is not well appropriate.).

This work summarizes the definitions and descriptive epidemiological data for DLGG and PCNST. DLGGs account for approximately 15 % of all gliomas, and incidence rate is about 1/100,000 person-years or just a little less. Main prognostic factors (e.g., age, performance status, location, volume and growth rate of the tumor, extent of surgical resection, histology) are discussed, and it is shown how they influence survival. Recent literature proposes a lot of new spontaneous prognostic factors, but until now, just a few are validated. In the other hand, little data are available to define best combinations of the different therapeutic strategies (successive surgeries, chemotherapy, radiotherapy, and new treatments).

This work proposes new efficient methodology to evaluate medical care and quality of life. The developments of modern informatics technology will revolutionize our methods of recording data. Collaboration between all medical specialties (including epidemiology and biostatistics) and development of large databases are the keys of efficiency for the future.

This chapter also summarizes knowledge of risk factors for DLGG and PCNST and proposes classical and new directions for searching etiologies for these tumors.

Keywords

Brain tumor Database Epidemiology Glioma Low-grade glioma Neuro-epidemiology Neuro-oncology Neuropathology Neurosurgery 

References

  1. 1.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumours of the central nervous system. Lyon: International Agency for Research on Cancer; 2007.Google Scholar
  2. 2.
    Arora RS, Alston RD, Eden TOB, Estlin EJ, Moran A, Geraci M, et al. Are reported increases in incidence of primary CNS tumours real? An analysis of longitudinal trends in England, 1979–2003. Eur J Cancer. 2010;46:1607–16.PubMedCrossRefGoogle Scholar
  3. 3.
    Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, Il’yasova D, et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer. 2008;113 Suppl 7:1953–68.PubMedCrossRefGoogle Scholar
  4. 4.
    Kleihues P, Cavenee WK. Tumours of the nervous system pathology and genetics, World health classification of tumors. Lyon: International Agency for Research on Cancer; 2000.Google Scholar
  5. 5.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.PubMedCrossRefGoogle Scholar
  6. 6.
    McCarthy BJ, Surawicz T, Bruner JM, Kruchko C, Davis F. Consensus conference on brain tumor definition for registration. Neurooncology. 2002;4:134–45.Google Scholar
  7. 7.
    McCarthy BJ, Kruchko C. Central Brain Tumor Registry of United States. Consensus conference on cancer registration of brain and central nervous system tumors. Neurooncology. 2005;7:196–201.Google Scholar
  8. 8.
    Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary brain tumors: current concepts and review of the literature. Neurooncology. 2002;4:278–99.Google Scholar
  9. 9.
    Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, et al. Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst. 2011;103:714–36.PubMedCrossRefGoogle Scholar
  10. 10.
    DeAngelis LM. Brain tumors. N Engl J Med. 2001;344:114–23.PubMedCrossRefGoogle Scholar
  11. 11.
    Bauchet L, Rigau V, Mathieu-Daudé H, Figarella-Branger D, Hugues D, Palusseau L, et al. French brain tumor data bank: methodology and first results on 10,000 cases. J Neurooncol. 2007;84:189–99.PubMedCrossRefGoogle Scholar
  12. 12.
    Bauchet L, Rigau V, Mathieu-Daudé H, Fabbro-Peray P, Palenzuela G, Figarella-Branger D, et al. Clinical epidemiology for childhood primary central nervous system tumors. J Neurooncol. 2009;92:87–98.PubMedCrossRefGoogle Scholar
  13. 13.
    Wöhrer A, Waldhör T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mösenbacher U, et al. The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol. 2009;95:401–11.PubMedCrossRefGoogle Scholar
  14. 14.
    CBTRUS. CBTRUS 2009–2010 eighteen states statistical report tables. Published by the Central Brain Tumor Registry of the United States, Hinsdale. 2009. Available at website: http://www.cbtrus.org/2007-2008/2007-2008.html. Accessed 17 Apr 2012.
  15. 15.
    CBTRUS. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004–2007. Published by the Central Brain Tumor Registry of the United States, Hinsdale. 2011. Available at website: http://www.cbtrus.org/2011-NPCR-SEER/WEB-0407-Report-3-3-2011.pdf Accessed 03 Mars 2011.
  16. 16.
    CBTRUS. Central Brain Tumor Registry of the United States, statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004–2008. 2012. http://www.cbtrus.org/2012-NPCR-SEER/CBTRUS_Report_2004-2008_3-23-2012.pdf. Accessed 17 Apr 2012.
  17. 17.
    Rigau V, Zouaoui S, Mathieu-Daudé H, Darlix A, Maran A, Trétarre B, et al. French brain tumor ­database: 5-year histological results on 25 756 cases. Brain Pathol. 2011;21:633–44.PubMedCrossRefGoogle Scholar
  18. 18.
    Baldi I, Gruber A, Alioum A, Berteaud E, Lebailly P, Huchet A, et al. Descriptive epidemiology of CNS tumors in France: results from the Gironde Registry for the period 2000–2007. Neuro Oncol. 2011;13:1370–8.PubMedCrossRefGoogle Scholar
  19. 19.
    ENCR, European Network of Cancer Registries. Recommendations for coding tumours of the brain and central nervous system. Development and Recommendations on Cancer Registration and Standards/Working Groups: Tumours of the Brain and Central Nervous System crossed PDF link: English. Distributed in 1998. Available at: http://www.encr.com.fr. Accessed 17 Apr 2012.
  20. 20.
    Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International classification of diseases for oncology. 3rd ed. Geneva: World Health Organization; 2000.Google Scholar
  21. 21.
    Zouaoui S, Rigau V, Mathieu-Daudé H, Darlix A, Bessaoud F, Fabbro-Peray P, et al. French brain tumor database: general results on 40,000 cases, main current applications and future prospects. Neurochirurgie. 2012;58:4–13.PubMedCrossRefGoogle Scholar
  22. 22.
    Hartmann C, Mueller W, von Deimling A. Pathology and molecular genetics of oligodendroglial tumors. J Mol Med. 2004;82:638–55.PubMedCrossRefGoogle Scholar
  23. 23.
    McCarthy BJ, Propp JM, Davis FG, Burger PC. Time trends in oligodendroglial and astrocytic tumor incidence. Neuroepidemiology. 2008;30:34–44.PubMedCrossRefGoogle Scholar
  24. 24.
    Daumas-Duport C, Beuvon F, Varlet P, Fallet-Bianco C. Gliomas: WHO and Sainte-Anne Hospital classifications. Ann Pathol. 2000;20:413–28.PubMedGoogle Scholar
  25. 25.
    Mittler MA, Walters BC, Stopa EG. Observer reliability in histological grading of astrocytoma stereotactic biopsies. J Neurosurg. 1996;85:1091–4.PubMedCrossRefGoogle Scholar
  26. 26.
    Ruiz J, Lesser GJ. Low-grade gliomas. Curr Treat Options Oncol. 2009;10:231–42.PubMedCrossRefGoogle Scholar
  27. 27.
    Bristol RE. Low-grade glial tumors: are they all the same? Semin Pediatr Neurol. 2009;16:23–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Piepmeier JM. Current concepts in the evaluation and management of WHO grade II gliomas. J Neurooncol. 2009;92:253–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Claus EB, Black PM. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973–2001. Cancer. 2006;106:1358–63.PubMedCrossRefGoogle Scholar
  30. 30.
    Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109:93–108.PubMedCrossRefGoogle Scholar
  31. 31.
    Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol. 2004;108:49–56.PubMedCrossRefGoogle Scholar
  32. 32.
    Nielsen MS, Christensen HC, Kosteljanetz M, Johansen C. Incidence of and survival from oligodendroglioma in Denmark, 1943–2002. Neuro Oncol. 2009;11:311–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Sant M, Minicozzi P, Lagorio S, Børge Johannesen T, Marcos-Gragera R, Francisci S, et al. Survival of European patients with central nervous system tumors. Int J Cancer. 2012;131(1):173–85.PubMedCrossRefGoogle Scholar
  34. 34.
    Crocetti E, Trama A, Stiller C, Caldarella A, Soffietti R, Jaal J, et al. Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer. 2012;48(10):1532–42.PubMedCrossRefGoogle Scholar
  35. 35.
    Davis FG, Kupelian V, Freels S, McCarthy B, Surawicz T. Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro Oncol. 2001;3:152–8.PubMedGoogle Scholar
  36. 36.
    Porter KR, McCarthy BJ, Freels S, Kim Y, Davis FG. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol. 2010;12:520–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Cook MB, Dawsey SM, Freedman ND, Inskip PD, Wichner SM, Quraishi SM, et al. Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev. 2009;18:1174–82.PubMedCrossRefGoogle Scholar
  38. 38.
    Soffietti R, Baumert BG, Bello L, von Deimling A, Duffau H, Frénay M, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol. 2010;17:1124–33.PubMedCrossRefGoogle Scholar
  39. 39.
    Sanai N, Chang S, Berger MS. Low-grade gliomas in adults. J Neurosurg. 2011;115:948–65.PubMedCrossRefGoogle Scholar
  40. 40.
    Loiseau H, Bousquet P, Rivel J, Vital C, Kantor G, Rougier A, et al. Supratentorial low-grade astrocytomas in adults. Prognostic factors and therapeutic indications. Apropos of a series of 141 patients. Neurochirurgie. 1995;41:38–50.PubMedGoogle Scholar
  41. 41.
    Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20:2076–84.PubMedCrossRefGoogle Scholar
  42. 42.
    van Veelen ML, Avezaat CJ, Kros JM, van Putten W, Vecht C. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psychiatry. 1998;64:581–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Berger MS, Rostomily RC. Low grade gliomas: functional mapping resection strategies, extent of resection, and outcome. J Neurooncol. 1997;34:85–101.PubMedCrossRefGoogle Scholar
  44. 44.
    Duffau H, Capelle L. Preferential brain locations of low-grade gliomas. Cancer. 2004;100:2622–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Pallud J, Mandonnet E, Duffau H, Kujas M, Guillevin R, Galanaud D, et al. Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas. Ann Neurol. 2006;60:380–3.PubMedCrossRefGoogle Scholar
  46. 46.
    Rees J, Watt H, Jäger HR, Benton C, Tozer D, Tofts P, et al. Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation. Eur J Radiol. 2009;72:54–64.PubMedCrossRefGoogle Scholar
  47. 47.
    Mandonnet E, Delattre JY, Tanguy ML, Swanson KR, Carpentier AF, Duffau H, et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol. 2003;53:524–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Mandonnet E, Pallud J, Fontaine D, Taillandier L, Bauchet L, Peruzzi P, et al. Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection. Neurosurg Rev. 2010;33:91–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Bauman G, Lote K, Larson D, Stalpers L, Leighton C, Fisher B, et al. Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys. 1999;45:923–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Chang EF, Smith JS, Chang SM, Lamborn KR, Prados MD, Butowski N, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg. 2008;109:817–24.PubMedCrossRefGoogle Scholar
  51. 51.
    Chang EF, Clark A, Jensen RL, Bernstein M, Guha A, Carrabba G, et al. Multiinstitutional validation of the University of California at San Francisco low-grade glioma prognostic scoring system. J Neurosurg. 2009;111:203–10.PubMedCrossRefGoogle Scholar
  52. 52.
    Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26:1338–45.PubMedCrossRefGoogle Scholar
  53. 53.
    van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366:985–90.PubMedCrossRefGoogle Scholar
  54. 54.
    Blonski M, Taillandier L, Herbet G, Maldonado IL, Beauchesne P, Fabbro M, et al. Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life. J Neurooncol. 2012;106:353–66.PubMedCrossRefGoogle Scholar
  55. 55.
    van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12:583–93.PubMedCrossRefGoogle Scholar
  56. 56.
    McGirt MJ, Chaichana KL, Attenello FJ, Weingart JD, Than K, Burger PC, et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery. 2008;63:700–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Bauchet L, Mathieu-Daudé H, Fabbro-Peray P, Rigau V, Fabbro M, Chinot O, et al. Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro Oncol. 2010;12:725–35.PubMedCrossRefGoogle Scholar
  58. 58.
    Woehrer A, Slavc I, Waldhoer T, Heinzl H, Zielonke N, Czech T, et al. Incidence of atypical teratoid/rhabdoid tumors in children: a population-based study by the Austrian Brain Tumor Registry, 1996–2006. Cancer. 2010;116:5725–32.PubMedCrossRefGoogle Scholar
  59. 59.
    NCCN Guidelines. Central nervous system cancer. Version 1. 2012. http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed 17 Apr 2012.
  60. 60.
    McCarthy BJ, Rankin KM, Aldape K, Bondy ML, Brännström T, Broholm H, et al. Risk factors for oligodendroglial tumors: a pooled international study. Neuro Oncol. 2011;13:242–50.PubMedCrossRefGoogle Scholar
  61. 61.
    Gozé C, Bezzina C, Gozé E, Rigau V, Maudelonde T, Bauchet L, et al. 1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth. J Neurooncol. 2012;108(1):69–75.PubMedCrossRefGoogle Scholar
  62. 62.
    Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science. 2011;333:1453–5.PubMedCrossRefGoogle Scholar
  63. 63.
    Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, et al. Molecular classification of low-grade diffuse gliomas. Am J Pathol. 2010;177:2708–14.PubMedCrossRefGoogle Scholar
  64. 64.
    Ohgaki H, Kleihues P. Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol. 2011;28:177–83.PubMedCrossRefGoogle Scholar
  65. 65.
    Ohgaki H, Kim YH, Steinbach JP. Nervous system tumors associated with familial tumor syndromes. Curr Opin Neurol. 2010;23:583–91.PubMedCrossRefGoogle Scholar
  66. 66.
    Kyritsis AP, Bondy ML, Rao JS, Sioka C. Inherited predisposition to glioma. Neuro Oncol. 2010;12:104–13.PubMedCrossRefGoogle Scholar
  67. 67.
    Ron E, Modan B, Boice Jr JD, Alfandary E, Stovall M, Chetrit A, et al. Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med. 1988;319:1033–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Yonehara S, Brenner AV, Kishikawa M, Inskip PD, Preston DL, Ron E, et al. Clinical and epidemiologic characteristics of first primary tumors of the central nervous system and related organs among atomic bomb survivors in Hiroshima and Nagasaki, 1958–1995. Cancer. 2004;101:1644–54.PubMedCrossRefGoogle Scholar
  69. 69.
    Hemminki K, Tretli S, Sundquist J, Johannesen TB, Granström C. Familial risks in nervous-system tumours: a histology-specific analysis from Sweden and Norway. Lancet Oncol. 2009;10:481–8.PubMedCrossRefGoogle Scholar
  70. 70.
    Inskip PD, Hoover RN, Devesa SS. Brain cancer incidence trends in relation to cellular telephone use in the United States. Neuro Oncol. 2010;12:1147–51.PubMedCrossRefGoogle Scholar
  71. 71.
    INTERPHONE Study Group. Brain tumour risk in relation to mobile telephone use: results of the INTERPHONE international case-control study. Int J Epidemiol. 2010;39:675–94.CrossRefGoogle Scholar
  72. 72.
    Deltour I, Auvinen A, Feychting M, Johansen C, Klaeboe L, Sankila R, et al. Mobile phone use and incidence of glioma in the Nordic countries 1979–2008: consistency check. Epidemiology. 2012;23:301–7.PubMedCrossRefGoogle Scholar
  73. 73.
    Terry MB, Howe G, Pogoda JM, Zhang FF, Ahlbom A, Choi W, et al. An international case-control study of adult diet and brain tumor risk: a histology-specific analysis by food group. Ann Epidemiol. 2009;19:161–71.PubMedCrossRefGoogle Scholar
  74. 74.
    Sheweita SA, Sheikh BY. Can dietary antioxidants reduce the incidence of brain tumors? Curr Drug Metab. 2011;12:587–93.PubMedGoogle Scholar
  75. 75.
    Scheurer ME, El-Zein R, Thompson PA, Aldape KD, Levin VA, Gilbert MR, et al. Long-term anti-inflammatory and antihistamine medication use and adult glioma risk. Cancer Epidemiol Biomarkers Prev. 2008;17:1277–81.PubMedCrossRefGoogle Scholar
  76. 76.
    Ferris J, McCoy L, Neugut AI, Wrensch M, Lai R. HMG CoA reductase inhibitors, NSAIDs and risk of glioma. Int J Cancer. 2012;131(6):E1031–7.PubMedCrossRefGoogle Scholar
  77. 77.
    Samanic CM, De Roos AJ, Stewart PA, Rajaraman P, Waters MA, Inskip PD. Occupational exposure to pesticides and risk of adult brain tumors. Am J Epidemiol. 2008;167:976–85.PubMedCrossRefGoogle Scholar
  78. 78.
    Provost D, Cantagrel A, Lebailly P, Jaffré A, Loyant V, Loiseau H, et al. Brain tumours and exposure to pesticides: a case-control study in southwestern France. Occup Environ Med. 2007;64:509–14.PubMedCrossRefGoogle Scholar
  79. 79.
    Vinson F, Merhi M, Baldi I, Raynal H, Gamet-Payrastre L. Exposure to pesticides and risk of ­childhood cancer: a meta-analysis of recent epidemiological studies. Occup Environ Med. 2011;68:694–702.PubMedCrossRefGoogle Scholar
  80. 80.
    Felini MJ, Olshan AF, Schroeder JC, Carozza SE, Miike R, Rice T, et al. Reproductive factors and hormone use and risk of adult gliomas. Cancer Causes Control. 2009;20:87–96.PubMedCrossRefGoogle Scholar
  81. 81.
    Benson VS, Pirie K, Green J, Casabonne D, Beral V, Million Women Study Collaborators. Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. Br J Cancer. 2008;99:185–90.PubMedCrossRefGoogle Scholar
  82. 82.
    Schlehofer B, Hettinger I, Ryan P, Blettner M, Preston-Martin S, Little J, et al. Occupational risk factors for low grade and high grade glioma: results from an international case control study of adult brain tumours. Int J Cancer. 2005;113:116–25.PubMedCrossRefGoogle Scholar
  83. 83.
    Scheurer ME, Etzel CJ, Liu M, Barnholtz-Sloan J, Wiklund F, Tavelin B, et al. Familial aggregation of glioma: a pooled analysis. Am J Epidemiol. 2010;172:1099–107.PubMedCrossRefGoogle Scholar
  84. 84.
    Brain Tumor Epidemiology Consortium (BTEC). Available at website: http://epi.grants.cancer.gov/btec/. Accessed 17 Apr 2012.
  85. 85.
    Gu J, Liu Y, Kyritsis AP, Bondy ML. Molecular epidemiology of primary brain tumors. Neurotherapeutics. 2009;6:427–35.PubMedCrossRefGoogle Scholar
  86. 86.
    GLIOGENE. An international brain tumor family study. Available at website: http://www.gliogene.org/. Accessed 17 Apr 2012.
  87. 87.
    Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 2009;41:899–904.PubMedCrossRefGoogle Scholar
  88. 88.
    Wrensch M, Jenkins RB, Chang JS, Yeh RF, Xiao Y, Decker PA, et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet. 2009;41:905–8.PubMedCrossRefGoogle Scholar
  89. 89.
    Jenkins RB, Wrensch MR, Johnson D, Fridley BL, Decker PA, Xiao Y, et al. Distinct germ line polymorphisms underlie glioma morphologic heterogeneity. Cancer Genet. 2011;204:13–8.PubMedCrossRefGoogle Scholar
  90. 90.
    Yan H, Bigner DD, Velculescu V, Parsons DW. Mutant metabolic enzymes are at the origin of gliomas. Cancer Res. 2009;69:9157–9.PubMedCrossRefGoogle Scholar
  91. 91.
    Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174:1149–53.PubMedCrossRefGoogle Scholar
  92. 92.
    Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. Identification of a CpG island methylator phenotype that defines a ­distinct subgroup of glioma. Cancer Cell. 2010;17:510–22.PubMedCrossRefGoogle Scholar
  93. 93.
    Berntsson SG, Wibom C, Sjöström S, Henriksson R, Brännström T, Broholm H, et al. Analysis of DNA repair gene polymorphisms and survival in low-grade and anaplastic gliomas. J Neurooncol. 2011;105:531–8.PubMedCrossRefGoogle Scholar
  94. 94.
    Melin B. Genetic causes of glioma: new leads in the labyrinth. Curr Opin Oncol. 2011;23:643–7.PubMedCrossRefGoogle Scholar
  95. 95.
    Duffau H. Surgery of low-grade gliomas: towards a « functional neurooncology ». Curr Opin Oncol. 2009;21:543–9.PubMedCrossRefGoogle Scholar
  96. 96.
    Duffau H, Pallud J, Mandonnet E. Evidence for the genesis of WHO grade II glioma in an asymptomatic young adult using repeated MRIs. Acta Neurochir (Wien). 2011;153:473–7.CrossRefGoogle Scholar
  97. 97.
    Pallud J, Fontaine D, Duffau H, Mandonnet E, Sanai N, Taillandier L, et al. Natural history of incidental World Health Organization grade II gliomas. Ann Neurol. 2010;68:727–33.PubMedCrossRefGoogle Scholar
  98. 98.
    Gerin C, Pallud J, Grammaticos B, Mandonnet E, Deroulers C, Varlet P, et al. Improving the time-­machine: estimating date of birth of grade II gliomas. Cell Prolif. 2012;45:76–90.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  1. 1.Department of NeurosurgeryHôpital Gui de Chauliac, Centre Hospitalier UniversitaireMontpellierFrance
  2. 2.INSERM U1051, Institut des NeurosciencesMontpellierFrance
  3. 3.French Brain Tumor DataBase, Groupe de Neuro-Oncologie du Languedoc-Roussillon, Registre des Tumeurs de l’HéraultCentre de Lutte Contre le Cancer Val d’AurelleMontpellierFrance

Personalised recommendations